Sign up Australia
Proactive Investors - Run By Investors For Investors

Immuron watches several high-value NASH related deals

Microbiome company Immuron (ASX:IMC) is witnessing a series of high-value licensing merger & acquisition (LM&A) deals related to NASH (non-alcoholic steatohepatitis) assets.
Immuron watches several high-value NASH related deals
Immuron is currently running clinical trials in fatty-liver diseases

Gilead (NASDAQ:GILD) has paid a $100 million milestone payment to Phenex following its licensing deal of Phenex’s Farnesoid X Receptor NASH Phase I clinical program in 2015.

This latest NASH milestone payment re-affirms Immuron’s belief that the LM&A market surrounding NASH technologies will remain extremely attractive, and active, for the foreseeable future.

The company’s long-term strategy is to secure a partner at the right time for its fatty-liver program.

Immuron is currently running three Phase II clinical trials in fatty-liver diseases with its lead product candidate IMM-124E including NASH, ASH (Alcoholic Steatohepatitis) and Pediatric NASH.

Both the ASH and Pediatric NASH trials are funded by the U.S. National Institutes of Health (NIH).

IMM-124E works upstream, and on several pathways, to reduce liver inflammation and is thus a completely unique treatment option compared to other leading investigational agents.

IMM-124E has the potential to be one of the backbone therapies for NASH patients.

As the worldwide prevalence of obesity and diabetes reaches epidemic proportions, the unmet need for treatments continues to grow.

In 2015, Pharmaxis’ NASH assets (Phase 1) were licensed by Boehringer ingelheim for a total potential deal value of US$600 million.

View full IMC profile View Profile

Immuron Ltd Timeline

Newswire
June 08 2017
Newswire
May 30 2017

Related Articles

Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
bacteria
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February
1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use